SCCS Scientific Advice on the Safety of Triclocarban and Triclosan
The European Commission Scientific Committee on Consumer Safety (SCCS) has published its preliminary version of the scientific advice on the safety of Triclocarban and Triclosan as substances with potential endocrine disrupting properties in cosmetic products. The deadline for comments was set at 27 May 2022.

TRICLOCARBAN AND TRICLOSAN

Triclocarban and Triclosan are ingredients used widely as preservatives in cosmetics and personal care products. They are both included in Annex V (list of preservatives allowed in cosmetic products) of the European Cosmetics Regulation (No. 1223/2009).

Triclocarban (CAS number: 101-20-2) can be used as a preservative up to a concentration of 0.2% in ready for use preparation, subject to purity criteria (Annex V, entry 23). This ingredient is also included in the list of substances which cosmetic products must not contain except subject to the restrictions laid down (Annex III, entry 100). For use other than as a preservative, Triclocarban may be used in rinse-off products up to a maximum concentration of 1.5%, subject to purity criteria.

Triclosan (CAS number: 3380-34-5) can only be used as a preservative in cosmetics. It may be used up to a concentration of 0.2% in mouthwashes and up to 0.3% in other products like toothpastes, hand soaps, body soaps, deodorants (non-spray), face powders, etc. (Annex V, entry 25).

Both Triclosan and Triclocarban have been assessed several times by the European Commission’s Scientific Committee on Consumer Safety (SCCS) and previous committees. These SCCS opinions resulted in the existing regulatory measures that allow different concentration of these ingredients based on the type of product and function.

In early 2019, a priority list of 28 potential endocrine disruptors (not already covered by the bans of cosmetic regulation) was established by the Commission. From these 28 substances, 14 were considered as higher priority (Group A) and the other 14 were included in the low priority group (Group B). The public call for data for the considered higher priority substances was carried out in 2019. Triclocarban and Triclosan were included in the mentioned group for which the call of data took place. (see previous post)

During the call for data, stakeholders submitted scientific evidence to demonstrate the safety of Triclocarban and Triclosan in cosmetic products. The European Commission asked the SCCS to carry out a safety assessment on these two substances considering the information provided.

SCCS SCIENTIFIC ADVICE ON THE SAFETY OF TRICLOCARBAN AND TRICLOSAN

At its plenary meeting on 15-16 March, the SCCS adopted the preliminary version of the scientific advice on the safety of Triclocarban and Triclosan as substances with potential endocrine disrupting properties in cosmetic products.

Based on the available information, including the potential endocrine effects of these ingredients, the SCCS stated that the use of Triclocarban as a preservative in cosmetic products is safe up to a maximum concentration of 0.2% and that this ingredient is also safe up to a maximum concentration of 1.5% in rinse-off products when used individually or in combination, when used with a function other than preservative.

Regarding the use of Triclosan, the SCCS considers that it is safe as a preservative when used individually or in combination up to a maximum concentration of 0.03% in shower gel and hand soap, 0.2% in mouthwash and 0.3% in toothpaste, deodorant stick, face powder and blemish concealer. The SCCS concluded that Triclosan up to a concentration of 0.3% is not safe as preservative in body lotion, but it is safe if its concentration does not exceed 0.03% in this type of cosmetic products.

The SCCS preliminary opinion is open for comments until 27 May 2022.

If you wish to get more information on the safety of cosmetic ingredients, feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Scientific Committee on Consumer Safety (SCCS). Scientific Advice on the safety of Triclocarban and Triclosan as substances with potential endocrine disrupting properties in cosmetic products. SCCS/1643/22. 2022.

further
reading

medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »